The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humans Findings support further clinical development for prevention and treatment of dengue, which impacts millions
The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humansFindings support further clinical development for prevention and treatment of dengue, which impacts millions of people today and is poised to threaten many more due to climate changeResearch builds on Johnson & Johnson’s endu.
15.03.2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today the publication of new data in the journal Nature showing that an early-stage clinical candidate (JNJ-1802) provides strong protection against dengue in non-human . Seite 1
Dr Jeanne Bolger brings over 35 years of management experience in the pharmaceutical industry to the new Belgium-based vaccine technology company. Last month,
Dr Jeanne Bolger brings over 35 years of management experience in the pharmaceutical industry to the new Belgium-based vaccine technology company.Last month, AstriVax closed its funding round - led by